8 January 2016 - Sarilumab is an investigational, human monoclonal antibody directed against the IL-6 receptor that is intended for the treatment of patients with active, moderate-to-severe rheumatoid arthritis.

For more details, go to: http://en.sanofi.com/NasdaQ_OMX/local/press_releases/sanofi_and_regeneron_announce__1977254_08-01-2016!07_00_00.aspx